Isis initiates phase 2 study of ISIS-APOCIIIRx in hypertriglyceridemia patients

RELATED QUOTES

SymbolPriceChange
ISIS20.39-0.42

Isis Pharmaceuticals, Inc. (ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia. The three-month study will enroll approximately 100 patients who have triglyceride levels of 500 mg/dL or higher. The study will evaluate ISIS-APOCIIIRx as a monotherapy and in combination with fibrates in patients. The endpoints for the study include measurements of triglycerides both before and after eating and apoC-III levels in blood. The company said, "Following the encouraging results we observed in our Phase 1 study in healthy volunteers, we hope to achieve similar triglyceride reductions in patients with very high triglycerides in the Phase 2 study we have just initiated. Assuming these data are replicated, we plan to move rapidly into a Phase 3 study in the most severe patients with triglyceride levels greater than 1,000 mg/dL who have been unable to control their triglyceride levels with currently available treatments."

  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.

    Trading Center

    Yahoo! Finance on Facebook

    POLL

    Should Chinese companies be rebuilding America's infrastructure?

    Loading...
    Poll Choice Options